Integrating new technology into blood plasma fractionation

被引：0

作者：

Curling, J ^{[1
]}

机构：

[1] John Curling Consulting AB, Uppsala, Sweden

[2] ProMet BioSci Ltd, Cambridge CB4 07A, England

来源：

BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT | 2002年 / 15卷 / 09期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immune serum globulin is in high demand, and that demand will only increase. Yet despite product shortages, the complexities involved in creating new manufacturing processes discourage change. The benefits - increased yield, reduced costs, new technologies, and faster throughput - now make identifying the best place in the processing stream to make manufacturing changes a rewarding endeavor. Planned change always trumps losing market share or being forced to change by new regulations.

引用

页码：16 / +

页数：6